EDAP Granted European Market Clearance for Focal.One(R)

EDAP Granted European Market Clearance for Focal.One(R)

Positions Focal.One Robotic HIFU Device for Commercialization

LYON, France, June 18, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, announced today that it received CE
Mark (European regulatory approval) for Focal.One^®, its new and innovative
robotic HIFU device fully dedicated to focal therapy of prostate cancer.
Focal.One was showcased as world premiere at the European Urology Association
Congress in Milan, Italy on March 15-19, 2013.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "This is a
significant regulatory achievement and a key milestone as we received EU
market clearance for the first robotic HIFU device dedicated to a focal
targeted treatment approach.This CE mark positions Focal.One for full
commercialization in Europe and in many other countries. It confirms EDAP's
expertise in managing R&D and regulatory programs successfully. I wish to
deeply congratulate the EDAP team for their extraordinary efforts in bringing
Focal.One to market in a timely manner."

Mr. Oczachowski continued, "Utilizing a focal therapy approach to target the
cancer cells within the prostate gland for the treatment of prostate cancer is
gaining wider acceptance across the international urological community.
Combining into one unique HIFU device the latest imaging modalities, such as
MRI localization and contrast-enhanced ultrasound control, with the ultimate
dynamic focusing HIFU technology, Focal.One will offer an optimal focal
therapy of prostate cancer while preserving patient quality of life."

Focal.One is the first device fully dedicated to the focal approach for
prostate cancer therapy. It combines the three essential components to
efficiently perform a focal treatment: (i) state-of-the-art imaging to
localize tumors with the use of magnetic resonance imaging (MRI) combined with
real-time ultrasound, (ii) utmost precision of HIFU treatment focused on
identified targeted cancer areas only and (iii) immediate feedback on
treatment efficacy utilizing Contrast-Enhanced Ultrasound Imaging.

EDAP's unique and exclusive range of HIFU products, including Ablatherm
Integrated Imaging and Focal.One, has now the capacity to offer a wide array
of treatment options to patients with prostate cancer.


EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low occurrence of
side effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for surgery or
who prefer an alternative option, or for patients who failed radiotherapy
treatment, Ablatherm-HIFU is approved and commercialized in Europe as a
treatment for prostate cancer and is currently under regulatory review in the
U.S. following submission of the Pre-Market Approval Application in February
2013 after the completion ofa multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA. The
Company also develops its HIFU technology for the potential treatment of
certain other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith® range) for treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL). For more information on
the Company, please visit http://www.edap-tms.com, and

Forward-Looking Statements

In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. Such
statements are based on management's current expectations and are subject to a
number of uncertainties, including the uncertainties of the FDA PMA review
process, our ability to expand our U.S. operations and execute our growth
strategy and the market potential for our medical technologies, as well as
risks that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may cause such a
difference include, but are not limited to, those described in the Company's
filings with the Securities and Exchange Commission and in particular, in the
sections "Cautionary Statement on Forward-Looking Information" and "Risk
Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment
is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Blandine Confort
         Investor Relations / Legal Affairs
         EDAP TMS SA
         +33 4 72 15 31 72
         Stephanie Carrington
         The Ruth Group
Press spacebar to pause and continue. Press esc to stop.